THE NOVEL MENIN INHIBITOR ZE63-0302 HAS AN IMPRESSIVE SAFETY PROFILE AND UNIQUE CHEMISTRY THAT SUGGESTS IMPROVED EFFICACY AGAINST RESISTANCE MUTATIONS.

revumenib (SNDX-5613) - Syndax Pharma

balamenib (ZE63-0302) - Eilean Therap

https://library.ehaweb.org/eha/2024/eha2024-congress/422234/erin.hertlein.the.novel.menin.inhibitor.ze63-0302.has.an.impressive.safety.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29191%2Amarker%3D5099%2Afeatured%3D18527

Erin Hertlein; Amina Abdul-Aziz; James Lerma; Casie Furby; Marissa Long; Megan Johnstone; Andrew Orry; Polo Lam; Ruben Abagyan; Alexander Khvat; Nikolay Savchuk; Volodymyr Kysil; Hovhannes Gukasyan; Iain Dukes; Kate Dokukina; Oleg Mitkin; Ruben Karapetian; Alexey Ryakhovskiy; Elena Bulanova; Vladislav Parchinsky; John C. Byrd; Amy Burd

May 15, 2024